Single and multiple doses of Indacaterol, a novel once-daily β2-agonists, are well tolerated in patients with mild asthma

被引：0
|
作者：
Brookman, L
Knight, H
Wood, J
Perry, S
Tarral, A
Elharrar, B
Pascoe, S
机构：
[1] Novartis Horsham Res Ctr, Horsham, W Sussex, England
[2] Biotrial, Paris, France
[3] Aster Cephac, Paris, France
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2005.12.333
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
324
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF ONCE-DAILY SINGLE-INHALER INDACATEROL ACETATE/GLYCOPYRRONIUM BROMIDE/MOMETASONE FUROATE IN PATIENTS WITH UNCONTROLLED MODERATE-TO-SEVERE ASTHMA
    Gupta, S.
    Muthukumar, M.
    Marvel, J.
    Kaur, H.
    Ishikawa, R.
    Hasani, I
    Mtibaa, M.
    Olivenstein, R.
    VALUE IN HEALTH, 2020, 23 : S723 - S724
  • [22] Specific inspiratory muscle training in patients with mild asthma with high consumption of inhaled β2-agonists
    Weiner, P
    Berar-Yanay, N
    Davidovich, A
    Magadle, R
    Weiner, M
    CHEST, 2000, 117 (03) : 722 - 727
  • [23] Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma
    Buhl, Roland
    Nikolaev, Ivan
    Tillmann, Hanns-Christian
    Vaidya, Soniya
    Bartels, Christian
    Jain, Monish
    Jauernig, Juergen
    Kerstjens, Huib A. M.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2021, 70
  • [24] Multiple, Once-Daily, Oral Doses of 150 mg Ubrogepant Administered for 28 Days Are Generally Well Tolerated, With No Clinically Singnificant Elevation of Alanine Aminotransferase in Healthy Adult Males
    Ankrom, Wendy
    Bondiskey, Phung
    Liu, Wen
    Palcza, John
    Panebianco, Deborah
    Dockendorf, Marissa F.
    Matthews, Catherine
    Kraft, Walter K.
    Wagner, John A.
    Jakate, Abhijeet
    Marcantonio, Eugene E.
    NEUROLOGY, 2019, 92 (15)
  • [25] Once-daily saxagliptin added to metformin is well tolerated and provides sustained glycaemic control over 102 weeks in patients with type 2 diabetes
    Ravichandran, S.
    DeFronzo, R.
    Garber, A. J.
    Gross, J. L.
    Hissa, M. N.
    Duan, R. Y.
    Chen, R.
    DIABETOLOGIA, 2009, 52 : S60 - S60
  • [26] Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
    Mtibaa, Mondher
    Gupta, Subhajit
    Muthukumar, Madhusubramanian
    Marvel, Jessica
    Kaur, Harneet
    Ishikawa, Ryotaro
    Olivenstein, Ron
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 957 - 967
  • [27] Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases
    Kai M. Beeh
    Jutta Beier
    Advances in Therapy, 2009, 26 : 691 - 699
  • [28] Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases
    Beeh, Kai M.
    Beier, Jutta
    ADVANCES IN THERAPY, 2009, 26 (07) : 691 - 699
  • [29] Once-Daily Saxagliptin Added to Metformin Provides Sustained Glycemic Control and Is Well Tolerated over 102 Weeks in Patients with T2D
    Defronzo, Ralph A.
    Hissa, Miguel N.
    Garber, Alan J.
    Gross, Jorge Luiz
    Duan, Raina Yuyan
    Ravichandran, Shoba
    Chen, Roland
    DIABETES, 2009, 58 : A147 - A147
  • [30] Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)
    Gessner, Christian
    Kornmann, Oliver
    Maspero, Jorge
    van Zyl-Smit, Richard
    Kruell, Matthias
    Salina, Anna
    Gupta, Pritam
    Bostel, Sebastien
    Fucile, Sebastian
    Conde, Lorena Garcia
    Pfister, Pascal
    RESPIRATORY MEDICINE, 2020, 170
12345